A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma
Cancer · 2023
DOI: 10.1002/cncr.34985 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2023. Verfasst von Osnat Bairey und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel. Hauptthemen laut MEDLINE: Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Janssen Pharmaceuticals.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Elderly patients account for nearly 70% of all primary central nervous system lymphoma (PCNSL) cases. They cannot tolerate aggressive treatment and have poor prognosis with a median overall survival (OS) of less than 2 years and progression‐free survival (PFS) of 6–16 months. Ibrutinib penetrates the blood–brain barrier and has shown activity in PCNSL.
Methods
This prospective study investigated whether ibrutinib maintenance is feasible, and whether it can benefit elderly PCNSL patients in terms of expected 2‐year PFS. It is an open label, phase 2 study in newly diagnosed PCNSL patients 60–85 years old who responded to first‐line high‐dose methotrexate (HDMTX)‐based treatment with partial or complete response. Ibrutinib maintenance (560 mg/d) was continued until disease progression or intolerable toxicity.
Results
Twenty patients were enrolled, with a median age of 72 years (range, 61–80). Median time on ibrutinib maintenance was 12.5 (range, 2–46) months. Twelve patients stopped treatment: five due to central nervous system relapse and seven due to adverse events that were mainly grade 2. Five patients died (25%) all due to relapse. The 1‐ and 2‐year PFS are 90% and 72.6%, respectively, and the 2‐year OS is 89%.
Conclusions
The study reached its primary end points and also showed that ibrutinib maintenance is tolerated reasonably well by the elderly. Therefore, this study supports the concept that ibrutinib maintenance should be further evaluated as an optional consolidation measure in the elderly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Institute of Oncology, Neuro-Oncology Unit, Sheba Medical Center, Ramat Gan, Israel.
- Department of Neurology, Cognitive Neurology Clinic, Rabin Medical Center, Petach Tikva, Israel.
- Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.
- Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel.
ORCID-Profile: Osnat Bairey
Förderung
- Janssen Pharmaceuticals
Zitieren
APA
Bairey, O., Taliansky, A., Glik, A., Amiel, A., Yust-Katz, S., Gurion, R., Zektser, M., Porges, T., Sarid, N., Horowitz, N. A., Shina, T. T., Lebel, E., Cohen, A., Geiger, K. R., Raanani, P., Wolach, O., & Siegal, T. (2023). A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer. https://doi.org/10.1002/cncr.34985
Vancouver
Bairey O, Taliansky A, Glik A, Amiel A, Yust-Katz S, Gurion R, et al. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer. 2023. doi:10.1002/cncr.34985
BibTeX
@article{Bairey2023,
author = {Bairey, Osnat and Taliansky, Alisa and Glik, Amir and Amiel, Alexandra and Yust-Katz, Shlomit and Gurion, Ronit and Zektser, Miri and Porges, Tzvika and Sarid, Nadav and Horowitz, Netanel A and Shina, Tzahala Tzuk and Lebel, Eyal and Cohen, Amos and Geiger, Karyn Revital and Raanani, Pia and Wolach, Ofir and Siegal, Tali},
title = {A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34985}
}
EUVIMED